VCYT - VERACYTE, INC.
IEX Last Trade
40.93
-0.240 -0.586%
Share volume: 10,029
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$41.17
-0.24
-0.58%
Fundamental analysis
9%
Profitability
0%
Dept financing
2%
Liquidity
72%
Performance
4%
Performance
5 Days
0.46%
1 Month
-3.87%
3 Months
22.89%
6 Months
83.02%
1 Year
44.29%
2 Year
67.53%
Key data
Stock price
$40.93
DAY RANGE
$40.59 - $41.56
52 WEEK RANGE
$19.19 - $46.00
52 WEEK CHANGE
$43.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Marc A. Stapley
Region: US
Website: veracyte.com
Employees: 790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: veracyte.com
Employees: 790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.
Recent news